Cite
A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.
MLA
Tosi, Anna, et al. “A Paclitaxel-Hyaluronan Conjugate (ONCOFID-P-B™) in Patients with BCG-Unresponsive Carcinoma in Situ of the Bladder: A Dynamic Assessment of the Tumor Microenvironment.” Journal of Experimental & Clinical Cancer Research (17569966), vol. 43, no. 1, Apr. 2024, pp. 1–19. EBSCOhost, https://doi.org/10.1186/s13046-024-03028-5.
APA
Tosi, A., Parisatto, B., Gaffo, E., Bortoluzzi, S., & Rosato, A. (2024). A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment. Journal of Experimental & Clinical Cancer Research (17569966), 43(1), 1–19. https://doi.org/10.1186/s13046-024-03028-5
Chicago
Tosi, Anna, Beatrice Parisatto, Enrico Gaffo, Stefania Bortoluzzi, and Antonio Rosato. 2024. “A Paclitaxel-Hyaluronan Conjugate (ONCOFID-P-B™) in Patients with BCG-Unresponsive Carcinoma in Situ of the Bladder: A Dynamic Assessment of the Tumor Microenvironment.” Journal of Experimental & Clinical Cancer Research (17569966) 43 (1): 1–19. doi:10.1186/s13046-024-03028-5.